Q2 Earnings Estimate for BEAM Issued By Leerink Partnrs

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Investment analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for shares of Beam Therapeutics in a report issued on Tuesday, February 25th. Leerink Partnrs analyst M. Foroohar expects that the company will earn ($1.28) per share for the quarter. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. Leerink Partnrs also issued estimates for Beam Therapeutics' Q3 2025 earnings at ($1.27) EPS, Q4 2025 earnings at ($1.30) EPS and FY2025 earnings at ($5.11) EPS.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($1.09) earnings per share for the quarter, beating analysts' consensus estimates of ($1.25) by $0.16. The company had revenue of $30.00 million for the quarter, compared to the consensus estimate of $16.47 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The firm's quarterly revenue was down 90.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.73 EPS.

A number of other research firms also recently commented on BEAM. HC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Beam Therapeutics in a report on Friday. Cantor Fitzgerald upgraded Beam Therapeutics from a "neutral" rating to an "overweight" rating in a report on Wednesday, January 29th. Leerink Partners upgraded Beam Therapeutics from a "market perform" rating to an "outperform" rating and increased their price objective for the stock from $27.00 to $39.00 in a report on Wednesday, November 6th. Wedbush restated an "outperform" rating and issued a $57.00 price objective on shares of Beam Therapeutics in a report on Monday, January 13th. Finally, Guggenheim restated a "buy" rating and issued a $78.00 price objective on shares of Beam Therapeutics in a report on Thursday. Three analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $51.00.

Beam Therapeutics Price Performance

NASDAQ:BEAM traded down $1.24 during mid-day trading on Friday, reaching $25.10. The stock had a trading volume of 1,345,872 shares, compared to its average volume of 1,146,394. The business's 50 day moving average is $27.18 and its 200 day moving average is $25.96. Beam Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $40.65. The stock has a market cap of $2.10 billion, a P/E ratio of -14.26 and a beta of 1.92.

Insider Activity

In other news, CEO John M. Evans sold 30,000 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $26.75, for a total value of $802,500.00. Following the completion of the sale, the chief executive officer now directly owns 908,659 shares of the company's stock, valued at approximately $24,306,628.25. This represents a 3.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christine Bellon sold 1,241 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total value of $30,627.88. Following the completion of the sale, the insider now directly owns 102,968 shares of the company's stock, valued at $2,541,250.24. This represents a 1.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Beam Therapeutics

Several hedge funds have recently modified their holdings of the business. Wealthfront Advisers LLC bought a new position in Beam Therapeutics in the fourth quarter worth $41,000. GF Fund Management CO. LTD. bought a new position in Beam Therapeutics in the fourth quarter worth $43,000. Sterling Capital Management LLC lifted its position in Beam Therapeutics by 816.0% in the fourth quarter. Sterling Capital Management LLC now owns 2,409 shares of the company's stock worth $60,000 after purchasing an additional 2,146 shares during the period. Blue Trust Inc. lifted its position in Beam Therapeutics by 84.0% in the third quarter. Blue Trust Inc. now owns 3,135 shares of the company's stock worth $73,000 after purchasing an additional 1,431 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Beam Therapeutics by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,981 shares of the company's stock worth $75,000 after purchasing an additional 524 shares during the period. 99.68% of the stock is owned by institutional investors.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.